← All trials
NCT01288339
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2010
- Primary completion
- Jan 1, 2015
- Completion date
- Sep 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Espanol Multidisciplinario del Cancer DigestivoLead sponsor
- Hospital Universitari Son DuretaOverall official - principal investigator
- Hospital general Universitario de Ciudad RealOverall official - principal investigator
- Miguel Hernández UniversityOverall official - principal investigator
- Hosptial Morales MeseguerOverall official - principal investigator
- Hospital de Fuenlabrada de MadridOverall official - principal investigator
- Hospital Xeral Cies de VigoOverall official - principal investigator
- Hospital de Sant Pau i Santa Tecla de TarragonaOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Hospital General Universitario de CastellónOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- University of BarcelonaStudy chair
- AmgenCollaborator
- TFS Trial Form SupportCollaborator
- Hospital General YagueOverall official - principal investigator
- Clinica Universidad de NavarraOverall official - principal investigator
- University of ZaragozaOverall official - principal investigator
- Hospital Son LlatzerOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- Hospital Universitario Arnau de Vilanova de LleidaOverall official - principal investigator
- University of Las Palmas de Gran CanariaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.